The Australian federal health department is urging healthcare professionals to exercise extreme caution when utilizing artificial intelligence-powered medical scribing tools. This directive comes as regulators examine whether stronger safeguards are necessary for one of the fastest-growing technologies in modern healthcare, according to a report by The Guardian. While these AI systems have rapidly gained popularity by recording and summarizing doctor-patient conversations into clinical notes—thereby reducing administrative burdens—the government warns that rapid adoption has outpaced oversight.
Rising Adoption Sparks Regulatory Scrutiny
Documents obtained through freedom of information requests reveal significant concerns regarding patient privacy, informed consent, and the accuracy of medical records. Briefing papers prepared for Senate Estimates in February 2026 describe current AI scribe technologies as having "little oversight." Notably, some platforms are marketed as operating outside existing medical device regulations despite being actively used within clinical settings.
The urgency of this review is underscored by surging adoption rates. An online survey conducted by the Royal Australian College of General Practitioners (RACGP) indicates that the proportion of doctors using AI scribes nearly doubled from 22 percent in August 2024 to 40 percent by November 2025. Technology providers claim their platforms have processed hundreds of millions of consultations globally over the past 18 months, highlighting the scale at which this technology is being integrated into daily practice.
Privacy and Data Security Concerns
Beyond clinical accuracy, privacy has emerged as a major point of contention. Officials found that some providers promote their products as compliant with privacy standards while offering limited transparency about how patient information is actually processed. In several instances, healthcare workers may not realize that sensitive patient data is being transmitted to cloud servers located outside Australia, potentially exposing medical records to additional security risks.
"The government has identified significant variations in how clinics obtain permission before recording consultations," officials noted during the review process.
The Consent Debate and Regulatory Landscape
Patient consent remains a critical area of focus. The department argues that meaningful informed consent requires patients to fully understand both the benefits and limitations of AI-assisted documentation. Consumer groups have reported instances where patients were told they would need to find another healthcare provider if they declined the use of AI scribes during appointments, raising ethical questions about patient autonomy.
The regulatory landscape remains fragmented, with oversight shared between the Therapeutic Goods Administration (TGA), the Australian Health Practitioner Regulation Agency (Ahpra), and the Office of the Australian Information Commissioner. The TGA is currently reviewing whether these tools should be formally classified as medical devices, a decision that could bring many platforms under stricter scrutiny. A report on this classification is expected in the coming months.
